News & Events
-
MORE
news
ILIAS Biologics Inc. is successfully wrapping up the Phase 1 clinicial trial for our ILB-202, marking a global first in the systemic administration of engineered exosomes.
2023-10-11
-
MORE
news
BioTV Interviewed our co-CEO Taejin Ham
2022-08-24
-
MORE
news
ILIAS Biologics, Inc. signed a contract with KDDF to develop an exosome-based IDB treatment
2022-08-11
-
MORE
news
ILIAS Biologics signed a collaborative research agreement with JW Pharmaceutical
2022-06-14
-
MORE
news
Researchers of ILIAS published biodistribution and pharmacokinetics study of ILB-202 in Pharmaceutics
2022-05-24
-
MORE
news
ILIAS Biologics signed an MOU with HK inno.N for joint research
2022-05-27